UH Seidman is Actively Enrolling Patients in CAR-T Clinical Trials

UH Seidman Cancer Center Update | October 2019

By Paolo Caimi, MD


UH Seidman Cancer Center physicians are currently enrolling patients in the following two clinical trials:

CASE 2417 – Point of Care Manufactured AntiCD19 CAR-T Cells for Relapsed or Refractory Non Hodgkin’s Lymphoma

• This Phase I investigator-initiated trial evaluates the use of rapid, local manufacture of AntiCD19 CAR-T cells for the treatment of relapsed/refractory lymphomas. CAR-T cells are manufactured in the UH Seidman Cancer Center Cellular Therapy Lab for 8-12 days, allowing for treatment of patients who would otherwise not be able to wait for other cellular therapies  manufactured off-site.
• This trial is actively enrolling. Patients with CD19+ lymphomas who have failed two or more lines of therapy are eligible. 
• ClinicalTrials.gov #NCT03434769

JUNO 1417 ¬– AntiCD19 CAR-T Cells for Treatment of Chronic Lymphocytic Leukemia

• This Phase I industry-based trial examines the safety and activity of anti CD19 CAR-T cells in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
• This study is actively enrolling. Eligible patients include: High risk CLL patients who have failed 2 lines of therapy or standard risk patients who have failed 3 lines of treatment. 

For more information on either of these trials call 216-844-3951.